Novel administration of thrombopoietin

Details Novel administration of thrombopoietin Novel administration of thrombopoietin

A - Human Necessities

61

K

A61K 38/19 (2006.01) A61K 47/48 (2006.01) C07K 14/52 (2006.01)

Patent

CA 2242417

The present invention is directed to the surprising and unexpected finding that biologically active thrombopoietin materials can be administered with substantial therapeutic effect at dosage rates commensurate with previously reported administration of such materials, but in a single or low-multiple daily administration. Thus, the predicate of the present invention relates to the reversal of thrombocytopenia by administering to a patient having or in need of such treatment a single or low-multiple daily dose of a therapeutically effective amount of a thrombopoietin. The preferable dose of the active material ranges from about 1 to about 10 µg/kg body weight.

La présente invention concerne des résultats surprenants et inattendus relatifs à l'administration de matières contenant de la thrombopoïétine biologiquement active et produisant un effet thérapeutique considérable, à des doses égales en quantité aux doses des mêmes matières administrées antérieurement, mais en une seule prise quotidienne ou en un petit nombre de prises par jour. Ainsi, la présente invention est fondée sur la possibilité d'inverser la thrombocytopénie par l'administration à un patient justiciable d'un tel traitement, en une dose unique ou en un petit nombre de prises par jour, une quantité thérapeutiquement efficace d'une thrombopoïétine. La dose préférée a une valeur comprise environ entre 1 et 10 µg de matière active par kg de poids du patient.

Affiliated with

Also associated with

Rating

Novel administration of thrombopoietin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel administration of thrombopoietin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel administration of thrombopoietin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2069190